Alzheimer's disease (AD) is one of the most common forms of dementia, affecting more than
50 million people globally. The onset of AD is linked to age, smoking, obesity …

The treatment of central nervous system (CNS) malignancies, including brain cancers, is
limited by a number of obstructions, including the blood-brain barrier (BBB), the …

Oxytocin is a neuropeptide hormone that plays an important role in social bonding and
behavior. Recent studies indicate that oxytocin could be involved in the regulation of …

Alzheimer's disease (AD), as a neurodegenerative disorder, usually develops slowly but
gradually worsens. It accounts for approximately 70% of dementia cases worldwide, and is …

The administration of medicinal drugs orally or systemically limits the treatment of specific
central nervous system (CNS) illnesses, such as certain types of brain cancers. These …

Alzheimer's disease (AD) is the fifth leading cause of death on the planet. It hallmarks the
presence of amyloid plaques and neurofibrillary tangles in geriatric patients. The condition …

Liquid crystalline nanoparticles (LCNPs) are lipid self-assembled nanostructures that meet
plenty of advantageous features. The commonly used substrates for LCNPs preparation are …

Alzheimer's disease (AD) is a major neurological disease affecting elderly individuals
worldwide. Existing drugs only reduce the symptoms of the disease without addressing the …

Neuronanomedicine merges nanotechnology and neuroscience in the pursuit of
engineering therapeutic interventions for neurological disorders, including Alzheimer's …

Neurodegenerative disorders are chronic conditions related to brain malfunctions. The
presence of the blood-brain barrier creates obstacles to the management of central nervous …